$2.93 Billion in Sales Expected for DaVita Inc. (NYSE:DVA) This Quarter

Brokerages forecast that DaVita Inc. (NYSE:DVAGet Rating) will report $2.93 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for DaVita’s earnings, with the highest sales estimate coming in at $2.95 billion and the lowest estimate coming in at $2.92 billion. DaVita reported sales of $2.92 billion in the same quarter last year, which would suggest a positive year over year growth rate of 0.3%. The company is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that DaVita will report full-year sales of $11.82 billion for the current year, with estimates ranging from $11.78 billion to $11.90 billion. For the next year, analysts expect that the company will post sales of $12.20 billion, with estimates ranging from $12.11 billion to $12.31 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that follow DaVita.

DaVita (NYSE:DVAGet Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported $1.61 earnings per share for the quarter, missing analysts’ consensus estimates of $1.85 by ($0.24). DaVita had a net margin of 7.78% and a return on equity of 78.24%. The company had revenue of $2.82 billion during the quarter, compared to analyst estimates of $2.89 billion. During the same period in the prior year, the business earned $2.09 EPS. The business’s revenue for the quarter was down .1% on a year-over-year basis.

A number of research analysts recently commented on DVA shares. StockNews.com lowered shares of DaVita from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 5th. Truist Financial dropped their price objective on shares of DaVita from $125.00 to $110.00 in a research note on Friday, May 6th. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $130.50.

A number of hedge funds have recently made changes to their positions in DVA. Amundi Pioneer Asset Management Inc. lifted its stake in DaVita by 31.9% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 154,693 shares of the company’s stock valued at $8,398,000 after acquiring an additional 37,375 shares during the period. US Bancorp DE grew its holdings in DaVita by 18.0% during the 3rd quarter. US Bancorp DE now owns 2,267 shares of the company’s stock valued at $264,000 after buying an additional 346 shares in the last quarter. Public Sector Pension Investment Board grew its holdings in shares of DaVita by 3.0% in the third quarter. Public Sector Pension Investment Board now owns 11,314 shares of the company’s stock valued at $1,315,000 after purchasing an additional 330 shares in the last quarter. Bank of Nova Scotia boosted its stake in DaVita by 2.2% during the third quarter. Bank of Nova Scotia now owns 22,970 shares of the company’s stock worth $2,670,000 after buying an additional 494 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its stake in DaVita by 4.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 386,527 shares of the company’s stock worth $44,938,000 after buying an additional 14,972 shares during the period. 87.47% of the stock is currently owned by institutional investors.

Shares of NYSE:DVA opened at $97.78 on Friday. The company’s 50-day moving average price is $109.50 and its two-hundred day moving average price is $109.32. The company has a debt-to-equity ratio of 8.53, a current ratio of 1.29 and a quick ratio of 1.25. DaVita has a one year low of $91.73 and a one year high of $136.48. The stock has a market capitalization of $9.25 billion, a PE ratio of 11.64, a price-to-earnings-growth ratio of 1.15 and a beta of 1.13.

DaVita Company Profile (Get Rating)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Featured Stories

Get a free copy of the Zacks research report on DaVita (DVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.